TransMedics Group (NASDAQ:TMDX) Shares Gap Up – Still a Buy?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) gapped up before the market opened on Monday . The stock had previously closed at $61.70, but opened at $63.33. TransMedics Group shares last traded at $62.87, with a volume of 243,741 shares changing hands.

Analyst Ratings Changes

TMDX has been the topic of a number of analyst reports. TD Cowen decreased their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Piper Sandler lowered their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Oppenheimer reiterated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Trading Up 2.9 %

The firm’s 50 day moving average is $88.42 and its 200 day moving average is $128.74. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $2.13 billion, a PE ratio of 67.51 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.12) EPS. As a group, equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,180,642.53. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 19,417 shares of company stock worth $2,240,738 over the last ninety days. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of TransMedics Group

Several institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue purchased a new stake in shares of TransMedics Group during the third quarter valued at $2,560,000. Charles Schwab Investment Management Inc. grew its stake in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares during the period. Zacks Investment Management purchased a new position in shares of TransMedics Group during the third quarter valued at approximately $1,607,000. Vaughan Nelson Investment Management L.P. lifted its position in TransMedics Group by 24.3% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after purchasing an additional 64,872 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.